⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of SK pharmteco and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
SK pharmteco
↗Rancho Cordova, USA
SK pharmteco is a leading global contract development and manufacturing organization (CDMO) that provides comprehensive development and manufacturing services to the biopharmaceutical industry. The company specializes in small molecules, peptides, and viral vectors, supporting partners from early-stage development through commercial production.
As a subsidiary of SK Inc., the strategic investment company for South Korea's SK Group, SK pharmteco leverages a global network of cGMP facilities across the U.S., Europe, and South Korea. The company is focused on enabling innovation and delivering reliable, high-quality manufacturing solutions for complex therapies, including cell and gene therapies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$740M
Ownership:subsidiary
Status:operating
STOCK
Exchange:KRX
Ticker:034730 (Parent: SK Inc.)
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (CDMO)
Modalities:Small molecule, Peptides, Viral vectors, Cell therapy, Gene therapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:SK Inc.
Subsidiaries:Center for Breakthrough Medicines
Key Partnerships:Genethon (Gene therapy manufacturing), AaviGen (Gene therapy for heart failure), LOTTE BIOLOGICS (ADC capabilities)
COMPETITION
Position:Leader
Competitors:Lonza, Catalent, Thermo Fisher Scientific (Patheon), Samsung Biologics
LEADERSHIP
Key Executives:
Joerg Ahlgrimm - CEO
LINKS
Website:skpt.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with SK pharmteco. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.